Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is a biotechnology company that uses artificial intelligence, automation, and large-scale biological experimentation to accelerate the discovery and development of medicines. Its technology platform, known as the Recursion Operating System, integrates data from biology, chemistry, imaging, and machine learning to identify potential drug candidates and better understand disease biology.
The company develops therapies for areas including oncology, rare diseases, and neurological disorders. Its pipeline has included investigational treatments such as REC-994 for cerebral cavernous malformation and REC-4881 for familial adenomatous polyposis, while its discovery platform is also used to evaluate additional programs and potential drug targets. Recursion works independently and through collaborations with pharmaceutical and biotechnology companies.
Founded in 2013 and headquartered in Salt Lake City, Utah, Recursion has built an international technology and research presence. In 2024, the company completed a combination with Exscientia, another artificial intelligence-focused drug discovery company, expanding its capabilities in computational chemistry and therapeutic design. Recursion is led by co-founder and Chief Executive Officer Chris Gibson.
AI Generated. May Contain Errors.
Free RXRX Stock Alerts